Molecular structure of Prazosin, CAS Number: 19216-56-9
Prazosin (CAS 19216-56-9)
See product citations (9)
Application:
Prazosin is a useful α1 and α2B-adrenoceptor antagonist
CAS Number:
19216-56-9
Molecular Weight:
383.41
Molecular Formula:
C19H21N5O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Prazosin functions as an alpha-1 adrenergic receptor antagonist. It acts by competitively inhibiting the binding of norepinephrine to alpha-1 adrenergic receptors on vascular smooth muscle. At the molecular level, prazosin blocks the activation of alpha-1 adrenergic receptors, preventing the downstream signaling cascade that would normally lead to vasoconstriction. This mechanism of action allows for the investigation of the role of alpha-1 adrenergic receptors in various physiological processes. Prazosin′s mechanism of action at the cellular level provides insight into the specific interactions between norepinephrine and alpha-1 adrenergic receptors.
Prazosin (CAS 19216-56-9) References
- Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs. | Paul, P., et al. 1999. J Pharmacol Exp Ther. 290: 334-40. PMID: 10381796
- Pharmacological characterization of melatonin binding sites in Syrian hamster hypothalamus. | Pickering, DS. and Niles, LP. 1990. Eur J Pharmacol. 175: 71-7. PMID: 2157597
- Prazosin-Conjugated Matrices Based on Biodegradable Polymers and α-Amino Acids--Synthesis, Characterization, and in Vitro Release Study. | Oledzka, E., et al. 2015. Molecules. 20: 14533-51. PMID: 26274943
- Treatment of Post-Traumatic Stress Disorders with the Alpha-1 Adrenergic Antagonist Prazosin. | Simon, PY. and Rousseau, PF. 2017. Can J Psychiatry. 62: 186-198. PMID: 27432823
- Alcohol withdrawal symptoms predict corticostriatal dysfunction that is reversed by prazosin treatment in alcohol use disorder. | Sinha, R., et al. 2022. Addict Biol. 27: e13116. PMID: 34856641
- Efficacy and acceptability of psychotherapeutic and pharmacological interventions for trauma-related nightmares: A systematic review and network meta-analysis. | Zhang, Y., et al. 2022. Neurosci Biobehav Rev. 139: 104717. PMID: 35661755
- Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder. | Geldenhuys, C., et al. 2022. CNS Drugs. 36: 721-737. PMID: 35688992
- Prazosin improves neurogenic acute heart failure through downregulation of fibroblast growth factor 23 in rat hearts. | Pan, JY., et al. 2022. Chin J Physiol. 65: 179-186. PMID: 36073566
- Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. | Stanaszek, WF., et al. 1983. Drugs. 25: 339-84. PMID: 6303744
- Self-poisoning with prazosin. | Rygnestad, TK. and Dale, O. 1983. Acta Med Scand. 213: 157-8. PMID: 6837333
- Clinical pharmacokinetics of prazosin. | Jaillon, P. 1980. Clin Pharmacokinet. 5: 365-76. PMID: 6994981
- Prazosin dynamics in hypertension: relationship to plasma concentration. | Seideman, P., et al. 1981. Clin Pharmacol Ther. 30: 447-54. PMID: 7285478
- Prazosin kinetics and effectiveness in renal failure. | Lowenthal, DT., et al. 1980. Clin Pharmacol Ther. 27: 779-83. PMID: 7379445
- Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. | Mathé, JM., et al. 1996. Eur J Pharmacol. 309: 1-11. PMID: 8864686
- Prazosin first-pass metabolism and hepatic extraction in the dog. | Rubin, P., et al. 1979. J Cardiovasc Pharmacol. 1: 641-7. PMID: 94630
Inhibitor of:
alpha2B-AR.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Prazosin, 1 mg | sc-280021 | 1 mg | $108.00 |